Mitochondrial and metabolic-based protective strategies in Huntington's disease: The case of creatine and coenzyme Q

Reviews in the Neurosciences

Volumn 23, Issue 1, 2012, Pages 13-28

  Naia, Luana ^a,b   Ribeiro, Maria Joo ^a,b   Rego, A Cristina ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Huntington's disease; metabolic dysfunction; mitochondria; neuroprotection

Indexed keywords

ALPHA TOCOPHEROL; CREATINE; HUNTINGTIN; MITOCHONDRIAL DNA; POLYGLUTAMINE; UBIDECARENONE;

BIOENERGY; CAG REPEAT; CALCIUM HOMEOSTASIS; DNA DAMAGE; GLUCOSE METABOLISM; HUMAN; HUNTINGTON CHOREA; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; CREATINE; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTON DISEASE; METABOLIC DISEASES; MITOCHONDRIAL DISEASES; NERVE TISSUE; UBIQUINONE;

EID: 84860539153     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/rns.2011.060     Document Type: Review

References (190)

1. Acevedo-Torres, K., Berr í os, L., Rosario, N., Dufault, V., Skatchkov, S., Eaton, M.J., Torres-Ramos, C.A., and Ayala-Torres, S. (2009). Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease. DNA Repair 8, 126-136.
2. Adhihetty, P.J. and Beal, M.F. (2008). Creatine and its potential therapeutic value for targeting cellular energy impairment in neuro-degenerative diseases. Neuromol. Med. 10, 275-290.
3. Almeida, S., Sarmento-Ribeiro, A.B., Januário, C., Rego, A.C., and Oliveira, C.R. (2008). Evidence of apoptosis and mitochondrial abnormalities in peripheral blood cells of Huntington's disease patients. Biochem. Biophys. Res. Commun. 374, 599-603.
4. Almeida, S., Cunha-Oliveira, T., Laço, M., Oliveira, C.R., and Rego, A.C. (2010). Dysregulation of CREB activation and histone acetylation in 3-nitropropionic acid-treated cortical neurons: prevention by BDNF and NGF. Neurotox. Res. 17, 399-405.
5. Andreassen, O.A., Dedeoglu, A., Ferrante, R.J., Jenkins, B.G., Ferrante, K.L., Thomas, M., Friedlich, A., Browne, S.E., Schilling, G., Borchelt, D.R., et al. (2001). Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 8, 479-491. (Pubitemid 32566138)
6. Andrew, S.E., Goldberg, Y.P., Kremer, B., Telenius, H., Theilmann, J., Adam, S., Starr, E., Squitieri, F., Lin, B., Kalchman, M.A., et al. (1993). The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat. Genet. 4, 398-403. (Pubitemid 23231490)
7. Arenas, J., Campos, Y., Ribacoba, R., Martín, M.A., Rubio, J.C., Ablanedo, P., and Cabello, A. (1998). Complex I defect in muscle from patients with Huntington's disease. Ann. Neurol. 43, 397-400. (Pubitemid 28113606)
8. Arning, L., Kraus, P.H., Valentin, S., Saft, C., Andrich, J., and Epplen, J.T. (2005). NR2A and NR2B receptor gene variations modify age at onset in Huntington disease. Neurogenetics 6, 25-28. (Pubitemid 40394827)
9. Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R., and Finkbeiner, S. (2004). Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810. (Pubitemid 39434070)
10. Auinger, P., Kieburtz, K., and McDermott, M.P. (2010). The relationship between uric acid levels and Huntington's disease progression. Mov. Disord. 25, 224-228.
11. Aylward, E.H., Rosenblatt, A., Field, K., Yallapragada, V., Kieburtz, K., McDermott, M., Raymond, L.A., Almqvist, E.W., Hayden, M., and Ross, C.A. (2003). Caudate volume as an outcome measure in clinical trials for Huntington's disease: a pilot study. Brain Res. Bull. 62, 137-141. (Pubitemid 37443659)
12. Aziz, N.A., van der Burg, J.M.M., Landwehrmeyer, G.B., Brundin, P., Stijnen, T., and Roos, R.A.C. (2008). Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 71, 1506-1513.
13. Bae, B.I., Xu, H., Igarashi, S., Fujimuro, M., Agrawal, N., Taya, Y., Hayward, S.D., Moran, T.H., Montell, C., Ross, C.A., et al. (2005). p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47, 29-41. (Pubitemid 40922848)
14. Bahadorani, S. and Hilliker, A.J. (2008). Antioxidants cannot suppress the lethal phenotype of a Drosophila melanogaster model of Huntington's disease. Genome 51, 392-395. (Pubitemid 351768973)
15. Banoei, M.M., Houshmand, M., Panahi, M.S., Shariati, P., Rostami, M., Manshadi, M.D., and Majidizadeh, T. (2007). Huntington's disease and mitochondrial DNA deletions: event or regular mechanism for mutant huntingtin protein and CAG repeats expansion? Cell. Mol. Neurobiol. 27, 867-875.
16. Bates, G. (2003). Huntingtin aggregation and toxicity in Huntington's disease. Lancet 361, 1642-1644. (Pubitemid 36579005)
17. Beal, M.F. (2011). Neuroprotective effects of creatine. Amino Acids 40, 1305-1313.
18. Benard, G., Bellance, N., James, D., Parrone, P., Fernandez, H., Letellier, T., and Rossignol, R. (2007). Mitochondrial bioenerget-ics and structural network organization. J. Cell Sci. 120, 838-848. (Pubitemid 46523485)
19. Benchoua, A., Trioulier, Y., Zala, D., Gaillard, M.C., Lefort, N., Dufour, N., Saudou, F., Elalouf, J.M., Hirsch, E., Hantraye, P., et al. (2006). Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol. Biol. Cell 17, 1652-1663. (Pubitemid 44011583)
20. Bender, A., Auer, D.P., Merl, T., Reilmann, R., Saemann, P., Yassouridis, A., Bender, J., Weindl, A., Dose, M., Gasser, T., et al. (2005). Creatine supplementation lowers brain glutamate levels in Huntington's disease. J. Neurol. 252, 36-41. (Pubitemid 40179016)
21. Benn, C.L., Sun, T., Sadri-Vakili, G., McFarland, K.N., DiRocco, D.P., Yohrling, G.J., Clark, T.W., Bouzou, B., and Cha, J.H. (2008). Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J. Neurosci. 28, 10720-10733.
22. Bezprozvanny, I. and Hayden, M.R. (2004). Deranged neuronal calcium signaling and Huntington disease. Biochem. Biophys. Res. Commun. 322, 1310-1317. (Pubitemid 39164659)
23. Björkqvist, M., Petersén, A., Bacos, K., Isaacs, J., Norlén, P., Gil, J., Popovic, N., Sundler, F., Bates, G.P., Tabrizi, S.J., et al. (2006). Progressive alterations in the hypothalamic-pituitary- adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum. Mol. Genet. 15, 1713-1721. (Pubitemid 43904837)
24. Boesgaard, T.W., Nielsen, T.T., Josefsen, K., Hansen, T., Jørgensen, T., Pedersen, O., N ørremølle, A., Nielsen, J.E., and Hasholt, L. (2009). Huntington's disease does not appear to increase the risk of diabetes mellitus. J. Neuroendocrinol. 21, 770-776.
25. Brouillet, E., Jacquard, C., Bizat, N., and Blum, D. (2005). 3-Nitrop-ropionic acid: a mitochondrial toxin to uncover physiopathologi-cal mechanisms underlying striatal degeneration in Huntington's disease. J. Neurochem. 95, 1521-1540. (Pubitemid 41804051)
26. Browne, S.E. (2008). Mitochondria and Huntington's disease patho-genesis. Insight from genetic and chemical models. Ann. NY Acad. Sci. 1147, 358-382.
27. Byvaltsev, V., Sudakov, N., Nikiforov, S., and Konstantinov, Y. (2010). Mitochondrial dysfunction and neurodegenerative diseases. World Neurosurg. 74, 10-12.
28. Cardoso, S.M., Santana, I., Swerdlow, R.H., and Oliveira, C.R. (2004). Mitochondria dysfunction of Alzheimer's disease cybrids enhances A β toxicity. J. Neurochem. 89, 1417-1426. (Pubitemid 38802663)
29. Cattaneo, E., Rigamonti, D., Goffredo, D., Zuccato, C., Squitieri, F., and Sipione, S. (2001). Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci. 24, 182-188. (Pubitemid 32166824)
30. Cattaneo, E., Zuccato, C., and Tartari, M. (2005). Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 6, 919-930. (Pubitemid 41753086)
31. Caviston, J.P. and Holzbaur, E.L. (2009). Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol. 19, 147-155.
32. Ceddia, R.B. and Sweeney, G. (2004). Creatine supplementation increases glucose oxidation and AMPK phosphorylation and reduces lactate production in L6 rat skeletal muscle cells. J. Physiol. 555, 409-421. (Pubitemid 38380000)
33. Celsi, F., Pizzo, P., Brini, M., Leo, S., Fotino, C., Pinton, P., and Rizzuto, R. (2009). Mitochondria, calcium and cell death: a deadly triad in neurodegeneration. Biochim. Biophys. Acta 1787, 335-344.
34. Chaturvedi, R.K., Adhihetty, P., Shukla, S., Hennessy, T., Calingasan, N., Yang, L., Starkov, A., Kiaei, M., Cannella, M., Sassone, J., et al. (2009). Impaired PGC-1alpha function in muscle in Huntington's disease. Hum. Mol. Genet. 18, 3048-3065.
35. Chen, C.M., Wu, Y.R., Cheng, M.L., Liu, J.L., Lee, Y.M., Lee, P.W., Soong, B.W., and Chiu, D.T. (2007). Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. Biochem. Biophys. Res. Commun. 359, 335-340. (Pubitemid 46880509)
36. Chomyn, A., Lai, S.T., Shakeley, R., Bresolin, N., Scarlato, G., and Attardi, G. (1994). Platelet-mediated transformation of mtDNA-less human cells: analysis of phenotypic variability among clones from normal individuals-and complementation behavior of the tRNALys mutation causing myoclonic epilepsy and ragged red fibers. Am. J. Hum. Genet. 54, 966-974.
37. Choo, Y.S., Johnson, G.V., MacDonald, M., Detloff, P.J., and Lesort, M. (2004). Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 13, 1407-1420. (Pubitemid 39023049)
38. Ciarmiello, A., Cannella, M., Lastoria, S., Simonelli, M., Frati, L., Rubinsztein, D.C., and Squitieri, F. (2006). Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J. Nucl. Med. 47, 215-222. (Pubitemid 46780885)
39. Colin, E., Régulier, E., Perrin, V., Dürr, A., Brice, A., Aebischer, P., Déglon, N., Humbert, S., and Saudou, F. (2005). Akt is altered in an animal model of Huntington's disease and in patients. Eur. J. Neurosci. 21, 1478-1488. (Pubitemid 40646594)
40. Cui, L., Jeong, H., Borovecki, F., Parkhurst, C.N., Tanese, N., and Krainc, D. (2006). Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neuro-degeneration. Cell 127, 59-69. (Pubitemid 44466642)
41. Davies, S.W., Turmaine, M., Cozens, B.A., DiFiglia, M., Sharp, A.H., Ross, C.A., Scherzinger, E., Wanker, E.E., Mangiarini, L., and Bates, G.P. (1997). Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548. (Pubitemid 27347243)
42. DiFiglia, M., Sapp, E., Chase, K., Schwarz, C., Meloni, A., Young, C., Martin, E., Vonsattel, J.P., Carraway, R., Reeves, S.A., et al. (1995). Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14, 1075-1081.
43. Djousse, L., Knowlton, B., Cupples, L.A., Marder, K., Shoulson, I., and Myers, R.H. (2002). Weight loss in early stage of Huntington's disease. Neurology 59, 1325-1330. (Pubitemid 35285981)
44. Duarte, A.I., Santos, M.S., Oliveira, C.R., and Rego, A.C. (2005). Insulin neuroprotection against oxidative stress in cortical neurons-Involvement of uric acid and glutathione antioxidant defenses. Free Radic. Biol. Med. 39, 876-889.
45. Esteves, A.R., Domingues, A.F., Ferreira, I.L., Januário, C., Swerdlow, R.H., Oliveira, C.R., and Cardoso, S.M. (2008). Mitochondrial function in Parkinson's disease cybrids containing an nt2 neuron-like nuclear background. Mitochondrion 8, 219-228.
46. Faber, P.W., Barnes, G.T., Srinidhi, J., Chen, J., Gusella, J.F., and MacDonald, M.E. (1998). Huntingtin interacts with a family of WW domain proteins. Hum. Mol. Genet. 7, 1463-1474. (Pubitemid 28429928)
47. Farrer, L.A. (1985). Diabetes mellitus in Huntington disease. Clin. Genet. 27, 62-67. (Pubitemid 15193407)
48. Feng, Z., Jin, S., Zupnick, A., Hoh, J., de Stanchina, E., Lowe, S., Prives, C., and Levine, A.J. (2006). p53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene 25, 1-7. (Pubitemid 43049998)
49. Ferrante, R.J., Andreassen, O.A., Jenkins, B.G., Dedeoglu, A., Kuemmerle, S., Kubilus, J.K., Kaddurah-Daouk, R., Hersch, S.M., and Beal, M.F. (2000). Neuroprotective effects of cre-atine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20, 4389-4397. (Pubitemid 30396603)
50. Ferrante, R.J., Andreassen, O.A., Dedeoglu, A., Ferrante, K.L., Jenkins, B.G., Hersch, S.M., and Beal, M.F. (2002). Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 22, 1592-1599. (Pubitemid 35386278)
51. Ferreira, I.L., Nascimento, M.V., Ribeiro, M., Almeida, S., Cardoso, S.M., Grazina, M., Pratas, J., Santos, M.J., Januário, C., Oliveira, C.R., et al. (2010). Mitochondrial-dependent apopto-sis in Huntington's disease human cybrids. Exp. Neurol. 222, 243-255.
52. Ferreira, I.L., Cunha-Oliveira, T., Nascimento, M.V., Ribeiro, M., Proença, M.T., Januário, C., Oliveira, C.R., and Rego, A.C. (2011). Bioenergetics dysfunction in Huntington's disease human cybrids. Exp. Neurol. 231, 127-134.
53. Futter, M., Diekmann, H., Schoenmakers, E., Sadiq, O., Chatterjee, K., and Rubinsztein, D.C. (2009). Wild-type but not mutant hun-tingtin modulates the transcriptional activity of liver X receptors. J. Med. Genet. 46, 438-446.
54. Gårseth, M., Sonnewald, U., White, L.R., Rød, M., Zwart, J.A., Nygaard, O., and Aasly, J. (2000). Proton magnetic resonance spectroscopy of cerebrospinal fluid in neurodegenerative disease: indication of glial energy impairment in Huntington chorea, but not Parkinson disease. J. Neurosci. Res. 60, 779-782. (Pubitemid 30399549)
55. Gauthier, L.R., Charrin, B.C., Borrell-Pagès, M., Dompierre, J.P., Rangone, H., Cordelières, F.P., De Mey, J., MacDonald, M.E., Lessmann, V., Humbert, S., et al. (2004). Huntingtin controls neu-rotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 11 8, 127-138. (Pubitemid 38902819)
56. Gil, J.M. and Rego, A.C. (2008). Mechanisms of neurodegeneration in Huntington's disease. Eur. J. Neurosci. 27, 2803-2820. (Pubitemid 351832229)
57. Gizatullina, Z.Z., Lindenberg, K.S., Harjes, P., Chen, Y., Kosinski, C.M., Landwehrmeyer, B.G., Ludolph, A.C., Striggow, F., Zierz, S., and Gellerich, F.N. (2006). Low stability of Huntington muscle mitochondria against Ca2+ in R6/2 mice. Ann. Neurol. 59, 407-411. (Pubitemid 43202500)
58. Gu, M., Gash, M.T., Mann, V.M., Javoy-Agid, F., Cooper, J.M., and Schapira, A.H. (1996). Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39, 385-389. (Pubitemid 26100764)
59. Guidetti, P., Charles, V., Chen, E.Y., Reddy, P.H., Kordower, J.H., Whetsell, W.O., Schwarcz, R., and Tagle, D.A. (2001). Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp. Neurol. 169, 340-350. (Pubitemid 32524428)
60. Gutekunst, C.A., Levey, A.I., Heilman, C.J., Whaleyt, W.L., Yi, H., Nash, N.R., Rees, H.D., Maddent, J.J., and Hersch, S.M. (1995). Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc. Natl. Acad. Sci. USA 92, 8710-8714.
61. Havel, L.S., Wang, C.E., Wade, B., Huang, B., Li, S., and Li, X.J. (2011). Preferential accumulation of N-terminal mutant hunting-tin in the nuclei of striatal neurons is regulated by phosphoryla-tion. Hum. Mol. Genet. 20, 1424-1437.
62. Hersch, S.M., Gevorkian, S., Marder, K., Moskowitz, C., Feigin, A., Cox, M., Como, P., Zimmerman, C., Lin, M., Zhang, L., et al. (2006). Creatine in Huntington disease is safe, tolerable, bio-available in brain and reduces serum 8OH2 ′ dG. Neurology 66, 250-252. (Pubitemid 43970166)
63. Hilditch-Maguire, P., Trettel, F., Passani, L.A., Auerbach, A., Persichetti, F., and MacDonald, M.E. (2000). Huntingtin: an iron-regulated protein essential for normal nuclear and perinu-clear organelles. Hum. Mol. Genet. 9, 2789-2797.
64. Ho, D.J., Calingasan, N.Y., Wille, E., Dumont, M., and Beal, M.F. (2010). Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp. Neurol. 225, 74-84.
65. Hult, S., Soylu, R., Björklund, T., Belgardt, B.F., Mauer, J., Br ü ning, J.C., Kirik, D., and Petersén, Å. (2011). Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocir-cuits. Cell Metab. 13, 428-439.
66. Huntington Study Group. (2001). A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57, 397-404.
67. Illuzzi, J.L., Vickers, C.A., and Kmiec, E.B. (2011). Modifications of p53 and the DNA damage response in cells expressing mutant form of the protein Huntingtin. J. Mol. Neurosci. 45, 256-268.
68. Inoue, K., Takai, D., Hosaka, H., Ito, S., Shitara, H., Isobe, K., LePecq, J.B., Segal-Bendirdjian, E., and Hayashi, J. (1997). Isolation and characterization of mitochondrial DNA-less lines from various mammalian cell lines by application of an antican-cer drug, ditercalinium. Biochem. Biophys. Res. Commun. 239, 257-260. (Pubitemid 27480351)
69. Iwata, A., Christianson, J.C., Bucci, M., Ellerby, L.M., Nukina, N., Forno, L.S., and Kopito, R.R. (2005). Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proc. Natl. Acad. Sci. USA 102, 13135-13140. (Pubitemid 41324991)
70. Jacobsen, J.C., Gregory, G.C., Woda, J.M., Thompson, M.N., Coser, K.R., Murthy, V., Kohane, I.S., Gusella, J.F., Seong, I.S., Macdonald, M.E., et al. (2011). HD CAG-correlated gene expression changes support a simple dominant gain of function. Hum. Mol. Genet. 20, 2846-2860.
71. Jazayeri, M., Andreyev, A., Will, Y., Ward, M., Anderson, C.M., and Clevenger, W. (2003). Inducible expression of a dominant negative DNA polymerase-gamma depletes mitochon-drial DNA and produces a rho0 phenotype. J. Biol. Chem. 278, 9823-9830. (Pubitemid 36800484)
72. Jenkins, B.G., Koroshetz, W.J., Beal, M.F., and Rosen, B.R. (1993). Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 43, 2689-2695. (Pubitemid 24004570)
73. Karasinska, J.M., Rinninger, F., Lütjohann, D., Ruddle, P., Franciosi, S., Kruit, J.K., Singaraja, R.R., Hirsch-Reinshagen, V., Fan, J., Brunham, L.R., et al. (2009). Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function. J. Neurosci. 29, 3579-3589.
74. Kasparová, S., Sumbalová, Z., Bystrický, P., Kucharská, J., Liptaj, T., Mlynárik, V., and Gvozdjá ková, A. (2006). Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease. Neurochem. Int. 48, 93-99. (Pubitemid 41832443)
75. Kazantsev, A.G. and Hersch, S.M. (2007). Drug targeting of dys-regulated transcription in Huntington's disease. Prog. Neurobiol. 83, 249-259. (Pubitemid 47588641)
76. Khan, S.M., Smigrodzki, R.M., and Swerdlow, R.H. (2007). Cell and animal models of mtDNA biology: progress and prospects. Am. J. Physiol. Cell Physiol. 292, 658-669.
77. Kim, Y.J., Yi, Y., Sapp, E., Wang, Y., Cuiffo, B., Kegel, K.B., Qin, Z.H., Aronin, N., and DiFiglia, M. (2001). Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc. Natl. Acad. Sci. USA 98, 12784-12789. (Pubitemid 33020022)
78. Kim, J., Amante, D.J., Moody, J.P., Edgerly, C.K., Bordiuk, O.L., Smith, K., Matson, S.A., Matson, W.R., Scherzer, C.R., Rosas, H.D., et al. (2010). Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease. Biochim. Biophys. Acta 1802, 673-681.
79. King, M.P. and Attardi, G. (1989). Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 246, 500-503. (Pubitemid 19273941)
80. Kirkwood, S.C., Su, J.L., Conneally, P., and Foroud, T. (2001). Progression of symptoms in the early and middle stages of Huntington disease. Arch. Neurol. 58, 273-278. (Pubitemid 32163165)
81. Koroshetz, W.J., Jenkins, B.G., Rosen, B.R., and Beal, M.F. (1997). Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. 41, 160-165. (Pubitemid 27082096)
82. Kosinski, C.M., Schlangen, C., Gellerich, F.N., Gizatullina, Z., Deschauer, M., Schiefer, J., Young, A.B., Landwehrmeyer, G.B., Toyka, K.V., Sellhaus, B., et al. (2007). Myopathy as a first symptom of Huntington's disease in a marathon runner. Mov. Disord. 22, 1637-1640. (Pubitemid 47477928)
83. Kuemmerle, S., Gutekunst, C.A., Klein, A.M., Li, X.J., Li, S.H., Beal, M.F., Hersch, S.M., and Ferrante, R.J. (1999). Huntington aggregates may not predict neuronal death in Huntington's disease. Ann. Neurol. 46, 842-849.
84. Kukat, A., Kukat, C., Brocher, J., Schäfer, I., Krohne, G., Trounce, I.A., Villani, G., and Seibel, P. (2008). Generation of rho0 cells utilizing a mitochondrially targeted restriction endonuclease and comparative analyses. Nucleic Acids Res. 36, e44.
85. Kuwert, T., Lange, H.W., Boecker, H., Titz, H., Herzog, H., Aulich, A., Wang, B.C., Nayak, U., and Feinendegen, L.E. (1993). Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease. J. Neurol. 241, 31-36. (Pubitemid 23342424)
86. Lee, J., Kim, C.H., Simon, D.K., Aminova, L.R., Andreyev, A.Y., Kushnareva, Y.E., Murphy, A.N., Lonze, B.E., Kim, K.S., Ginty, D.D., et al. (2005). Mitochondrial cyclic AMP response element-binding protein (CREB) mediates mitochondrial gene expression and neuronal survival. J. Biol. Chem. 280, 40398-40401. (Pubitemid 41780525)
87. Leenders, K.L., Frackowiak, R.S., Quinn, N., and Marsden, C.D. (1986). Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography. Mov. Disord. 1, 69-77.
88. Lenaz, G., Baracca, A., Fato, R., Genova, M.L., and Solaini, G. (2006). Mitochondrial complex I: structure, function, and implications in neurodegeneration. Ital. J. Biochem. 55, 232-253.
89. Leone, T.C., Lehman, J.J., Finck, B.N., Schaeffer, P.J., Wende, A.R., Boudina, S., Courtois, M., Wozniak, D.F., Sambandam, N., Bernal-Mizrachi, C., et al. (2005). PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 3, e101.
90. Li, S.H. and Li, X.J. (2004). Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet. 20, 146-154.
91. Li, J.L., Hayden, M.R., Warby, S.C., Durr, A., Morrison, P.J., Nance, M., Ross, C.A., Margolis, R.L., Rosenblatt, A., Squitieri, F. et al. (2006). Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study. BMC Med. Genet. 7, 71.
92. Lin, M.T. and Beal, M.F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787-795. (Pubitemid 44622683)
93. Lin, J., Wu, P.H., Tarr, P.T., Lindenberg, K.S., St-Pierre, J., Zhang, C.Y., Mootha, V.K., Jager, S., Vianna, C.R., Reznick, R.M., et al. (2004). Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 11 9, 121-135. (Pubitemid 39349325)
94. Lin, J., Handschin, C., and Spiegelman, B.M. (2005). Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 1, 361-370. (Pubitemid 43960626)
95. Lin, Y.S., Chen, C.M., Soong, B.W., Wu, Y.R., Chen, H.M., Yeh, W.Y., Wu, D.R., Lin, Y.J., Poon, P.W., Cheng, M.L., et al. (2011). Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease. J. Clin. Invest. 121, 1519-1523.
96. Lodi, R., Schapira, A.H., Manners, D., Styles, P., Wood, N.W., Taylor, D.J., and Warner, T.T. (2000). Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropal-lidoluysian atrophy. Ann. Neurol. 48, 72-76. (Pubitemid 30432433)
97. Luthi-Carter, R., Taylor, D.M., Pallos, J., Lambert, E., Amore, A., Parker, A., Moffitt, H., Smith, D.L., Runne, H., Gokce, O., et al. (2010). SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc. Natl. Acad. Sci. USA 107, 7927-7932.
98. Ma, Y., Bai, R.K., Trieu, R., and Wong, L.J. (2010). Mitochondrial dysfunction in human breast cancer cells and their transmito-chondrial cybrids. Biochim. Biophys. Acta 1797, 29-37.
99. MacDonald, M.E., Barnes, G., Srinidhi, J., Duyao, M.P., Ambrose, C.M., Myers, R.H., Gray, J., Conneally, P.M., Young, A., Penney, J., et al. (1993). Gametic but not somatic instability of CAG repeat length in Huntington's disease. J. Med. Genet. 30, 982-986. (Pubitemid 23356864)
100. Martin, E., Betuing, S., Pagès, C., Cambon, K., Auregan, G., Deglon, N., Roze, E., and Caboche, J. (2011a). Mitogen-and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-α promoter. Hum. Mol. Genet. 20, 2422-2434.
101. Martin, M., Trovó, L., Perga, S., Sadowska, A., Rasola, A., Chiara, F., and Dotti, C.G. (2011b). Cyp46-mediated cholesterol loss promotes survival in stressed hippocampal neurons. Neurobiol. Aging 32, 933-943.
102. Matthews, T., Yang, L., Jenkins, B.G., Ferrante, R.J., Rosen, R., Kaddurah-Daouk, R., and Beal, M.F. (1998). Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J. Neurosci. 18, 156-163. (Pubitemid 28046777)
103. Mazzola, J.L. and Sirover, M.A. (2002). Alteration of nuclear glycer-aldehyde-3-phosphate dehydrogenase structure in Huntington's disease fibroblasts. Brain Res. Mol. Brain Res. 100, 95-101. (Pubitemid 34465582)
104. Menalled, L.B., Patry, M., Ragland, N., Lowden, P.A., Goodman, J., Minnich, J., Zahasky, B., Park, L., Leeds, J., Howland, D., et al. (2010). Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline. PLoS One 5, e9793.
105. Milakovic, T. and Johnson, G.V. (2005). Mitochondrial respiration and ATP production are significantly impaired in stri-atal cells expressing mutant huntingtin. J. Biol. Chem. 280, 30773-30782. (Pubitemid 41291807)
106. Milakovic, T., Quintanilla, R.A., and Johnson, G.V. (2006). Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences. J. Biol. Chem. 281, 34785-34795. (Pubitemid 46036517)
107. Mitchell, I.J., Cooper, A.J., and Griffiths, M.R. (1999). The selective vulnerability of striatopallidal neurons. Prog. Neurobiol. 59, 691-719. (Pubitemid 29457588)
108. Mochel, F. and Haller, R.G. (2011). Energy deficit in Huntington disease: why it matters. J. Clin. Invest. 121, 493-499.
109. Moffitt, H., McPhail, G.D., Woodman, B., Hobbs, C., and Bates, G.P. (2009). Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease. PLoS One 4, e8025.
110. Nance, M.A. and Myers, R.H. (2001). Juvenile onset Huntington's disease-clinical and research perspectives. Ment. Retard. Dev. Disabil. Res. Rev. 7, 153-157. (Pubitemid 32843805)
111. Nelson, I., Hanna, M.G., Wood, N.W., and Harding, A.E. (1997). Depletion of mitochondrial DNA by ddC in untransformed human cell lines. Somat. Cell Mol. Genet. 23, 287-290. (Pubitemid 28162723)
112. Nucifora, F.C., Jr., Sasaki, M., Peters, M.F., Huang, H., Cooper, J.K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V.L., et al. (2001). Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science 291, 2423-2428. (Pubitemid 32231807)
113. O'Gorman, E., Beutner, G., Wallimann, T., and Brdiczka, D. (1996). Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brain. Biochim. Biophys. Acta 1276, 161-170. (Pubitemid 26308733)
114. Oláh, J., Klivényi, P., Gardián, G., Vécsei, L., Orosz, F., Kovacs, G.G., Westerhoff, H.V., and Ovádi, J. (2008). Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice. FEBS J. 275, 4740-4755.
115. 2+ buffering differences of intact neurons and astrocytes from cortex and striatum. J. Biol. Chem. 284, 5010-5020.
116. 2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. J. Neurosci. 26, 11174-11186. (Pubitemid 44772205)
117. Oliveira, J.M., Jekabsons, M.B., Chen, S., Lin, A., Rego, A.C., Gonçalves, J., Ellerby, L.M., and Nicholls, D.G. (2007). Mitochondrial dysfunction in Huntington's disease: the bioener-getics of isolated and in situ mitochondria from transgenic mice. J. Neurochem. 101, 241-249. (Pubitemid 46426480)
118. Ortega, Z., Díaz-Hernández, M., Maynard, C.J., Hernández, F., Dantuma, N.P., and Lucas, J.J. (2010). Acute polyglutamine expression in inducible mouse model unravels ubiquitin/protea-some system impairment and permanent recovery attributable to aggregate formation. J Neurosci. 30, 3675-3688.
119. Ostrowski, R., Piotrowski, P., Pankowska, T., and Smialek, M. (1998). Evaluation of morphological changes after treatment with coenzyme Q10 (CoQ10) in endothelin-1 induced experimental ischemia in the rat. Folia Neuropathol. 36, 185-188. (Pubitemid 128548565)
120. Panov, A.V., Gutekunst, C.A., Leavitt, B.R., Hayden, M.R., Burke, J.R., Strittmatter, W.J., and Greenamyre, J.T. (2002). Early mito-chondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5, 731-736. (Pubitemid 34827590)
121. Parker, W.D., Boyson, S.J., Luder, A.S., and Parks, J.K. (1990). Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington's disease. Neurology 40, 1231-1234. (Pubitemid 20244981)
122. Penney, J.B., Young, A.B., Shoulson, I., Starosta-Rubenstein, S., Snodgrass, S.R., Sanchez-Ramos, J., Ramos-Arroyo, M., Gomez, F., Penchaszadeh, G., Alvir, J., et al. (1990). Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov. Disord. 5, 93-99. (Pubitemid 20166182)
123. Perluigi, M., Poon, H.F., Maragos, W., Pierce, W.M., Klein, J.B., Calabrese, V., Cini, C., De Marco, C., and Butterfield, D.A. (2005). Proteomic analysis of protein expression and oxidative modification in R6/2 transgenic mice: a model of Huntington disease. Mol. Cell. Proteomics 4, 1849-1861. (Pubitemid 41830180)
124. Petersén, A. and Björkqvist, M. (2006). Hypothalamic- endocrine aspects in Huntington's disease. Eur. J. Neurosci. 24, 961-967. (Pubitemid 44268127)
125. Podolsky, S., Leopold, N.A., and Sax, D.S. (1972). Increased frequency of diabetes mellitus in patients with Huntington's chorea. Lancet i, 1356-1358.
126. Popovic, V., Svetel, M., Djurovic, M., Petrovic, S., Doknic, M., Pekic, S., Miljic, D., Milic, N., Glodic, J., Dieguez, C., et al. (2004). Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease. Eur. J. Endocrinol. 151, 451-455. (Pubitemid 39430262)
127. Powers, W.J., Haas, R.H., Le, T., Videen, T.O., Hershey, T., McGee-Minnich, L., and Perlmutter, J.S. (2007a). Normal platelet mito-chondrial complex I activity in Huntington's disease. Neurobiol. Dis. 27, 99-101. (Pubitemid 46921478)
128. Powers, W.J., Videen, T.O., Markham, J., McGee-Minnich, L., and Antenor-Dorsey, J. (2007b). Selective defect of in vivo glycoly-sis in early Huntington's disease striatum. Proc. Natl. Acad. Sci. USA 104, 2945-2949. (Pubitemid 46327983)
129. Powers, W.J., Haas, R.H., Le, T., Videen, T.O., Markham, J., and Perlmutter, J.S. (2011). Platelet mitochondrial complex I and I + III activities do not correlate with cerebral mitochondrial oxi-dative metabolism. J. Cereb. Blood Flow Metab. 31, e1-e5.
130. Reddy, P.H., Williams, M., and Tagle, D.A. (1999). Recent advances in understanding the pathogenesis of Huntington's disease. Trends Neurosci. 22, 248-255. (Pubitemid 29259990)
131. Rego, A.C. and de Almeida, L.P. (2005). Molecular targets and therapeutic strategies in Huntington's disease. Curr. Drug Targets CNS Neurol. Disord. 4,
132. Rigamonti, D., Bauer, J.H., De-Fraja, C., Conti, L., Sipione, S., Sciorati, C., Clementi, E., Hackam, A., Hayden, M.R., Li, Y., et al. (2000). Wild-type huntingtin protects from apoptosis upstream of caspase-3. J. Neurosci. 20, 3705-3713. (Pubitemid 30266233)
133. Rigamonti, D., Sipione, S., Goffredo, D., Zuccato, C., Fossale, E., and Cattaneo, E. (2001). Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. J. Biol. Chem. 276, 14545-14548.
134. Rockabrand, E., Slepko, N., Pantalone, A., Nukala, V.N., Kazantsev, A., Marsh, J.L., Sullivan, P.G., Steffan, J.S., Sensi, S.L., and Thompson, L.M. (2007). The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum. Mol. Genet. 16, 61-77. (Pubitemid 46156597)
135. Rong, J., McGuire, J.R., Fang, Z.H., Sheng, G., Shin, J.Y., Li, S.H., and Li, X.J. (2006). Regulation of intracellular trafficking of huntingtin-associated protein-1 is critical for TrkA protein levels and neurite outgrowth. J. Neurosci. 26, 6019-6030. (Pubitemid 44318368)
136. Rosenstock, T.R., Duarte, A.I., and Rego, A.C. (2010). Mitochondrial-associated metabolic changes and neurodegeneration in Huntington's disease-from clinical features to the bench. Curr. Drug Targets 11, 1218-1236.
137. Ross, C.A. and Poirier, M.A. (2005). Opinion: What is the role of protein aggregation in neurodegeneration? Nat. Rev. Mol. Cell Biol. 6, 891-898. (Pubitemid 41568738)
138. Ryu, H., Lee, J., Impey, S., Ratan, R.R., and Ferrante, R.J. (2005). Antioxidants modulate mitochondrial PKA and increase CREB binding to D-loop DNA of the mitochondrial genome in neurons. Proc. Natl. Acad. Sci. USA 102, 13915-13920. (Pubitemid 41377678)
139. Safdar, A., Little, J.P., Stokl, A.J., Hettinga, B.P., Akhtar, M., and Tarnopolsky, M.A. (2011). Exercise increases mitochondrial PGC-1alpha content and promotes nuclear-mitochondrial crosstalk to coordinate mitochondrial biogenesis. J. Biol. Chem. 286, 10605-10617.
140. Saft, C., Zange, J., Andrich, J., Müller, K., Lindenberg, K., Landwehrmeyer, B., Vorgerd, M., Kraus, P.H., Przuntek, H., and Schöls, L. (2005). Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov. Disord. 20, 674-679. (Pubitemid 41051778)
141. Sassone, J., Colciago, C., Cislaghi, G., Silani, V., and Ciammola, A. (2009). Huntington's disease: the current state of research with peripheral tissues. Exp. Neurol. 219, 385-397.
142. Savas, J.N., Ma, B., Deinhardt, K., Culver, B.P., Restituito, S., Wu, L., Belasco, J.G., Chao, M.V., and Tanese, N. (2010). A role for Huntington disease protein in dendritic RNA granules. J. Biol. Chem. 285, 13142-13153.
143. Sawa, A., Wiegand, G.W., Cooper, J., Margolis, R.L., Sharp, A.H., Lawler, J.F., Jr., Greenamyre, J.T., Snyder, S.H., and Ross, C.A. (1999). Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med. 5, 1194-1198. (Pubitemid 29474426)
144. Schatz, G. (1995). Mitochondria: beyond oxidative phosphorylation. Biochim. Biophys. Acta 1271, 123-126.
145. Schilling, G., Coonfield, M.L., Ross, C.A., and Borchelt, D.R. (2001). Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci. Lett. 315, 149-153. (Pubitemid 33079072)
146. Smith, K.M., Matson, S., Matson, W.R., Cormier, K., Del Signore, S.J., Hagerty, S.W., Stack, E.C., Ryu, H., and Ferrante, R.J. (2006). Dose ranging and efficacy study of high-dose coen-zyme Q10 formulations in Huntington's disease mice. Biochim. Biophys. Acta 1762, 616-626. (Pubitemid 43903119)
147. Soneson, C., Fontes, M., Zhou, Y., Denisov, V., Paulsen, J.S., Kirik, D., Petersén, A., and Huntington Study Group PREDICT-HD Investigators. (2010). Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiol. Dis. 40, 531-543.
148. Song, W., Chen, J., Petrilli, A., Liot, G., Klinglmayr, E., Zhou, Y., Poquiz, P., Tjong, J., Pouladi, M.A., Hayden, M.R., et al. (2011). Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat. Med. 17, 377-382.
149. Sorolla, M.A., Reverter-Branchat, G., Tamarit, J., Ferrer, I., Ros, J., and Cabiscol, E. (2008). Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic. Biol. Med. 45, 667-678.
150. Spargo, E., Everall, I.P., and Lantos, P.L. (1993). Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection. J. Neurol. Neurosurg. Psychiatry 56, 487-491. (Pubitemid 23171778)
151. Spierings, D., McStay, G., Saleh, M., Bender, C., Chipuk, J., Maurer, U., and Green, D.R. (2005). Connected to death: the (unexpur-gated) mitochondrial pathway of apoptosis. Science 310, 66-67. (Pubitemid 41434533)
152. Spinney, L. (2010). Uncovering the true prevalence of Huntington's disease. Lancet Neurol. 9, 760-761.
153. Squitieri, F., Falleni, A., Cannella, M., Orobello, S., Fulceri, F., Lenzi, P., and Fornai, F. (2010). Abnormal morphology of peripheral cell tissues from patients with Huntington disease. J. Neural Transm. 117, 77-83.
154. St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J.M., Rhee, J., Jäger, S., Handschin, C., Zheng, K., Lin, J., Yang, W., et al. (2006). Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127, 397-408. (Pubitemid 44572377)
155. Stack, E.C., Matson, W.R., and Ferrante, R.J. (2008). Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants. Ann. NY Acad. Sci. 1147, 79-92.
156. Steffan, J.S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B.L., Kazantsev, A., Schmidt, E., Zhu, Y.Z., Greenwald, M., et al. (2001). Histone deacetylase inhibitors arrest polyglu-tamine-dependent neurodegeneration in Drosophila. Nature 413, 739-743. (Pubitemid 33009952)
157. Suhr, S.T., Senut, M.C., Whitelegge, J.P., Faull, K.F., Cuizon, D.B., and Gage, F.H. (2001). Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. J. Cell Biol. 153, 283-294. (Pubitemid 34280215)
158. Sun, B., Fan, W., Balciunas, A., Cooper, J.K., Bitan, G., Steavenson, S., Denis, P.E., Young, Y., Adler, B., Daugherty, L. et al. (2002). Polyglutamine repeat length-dependent proteolysis of huntingtin. Neurobiol. Dis. 11, 111-122. (Pubitemid 35435679)
159. Swerdlow, R.H. (2007). Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. J. Neurosci. Res. 85, 3416-3428. (Pubitemid 350058530)
160. Swerdlow, R.H., Parks, J.K., Cassarino, D.S., Shilling, A.T., Bennett, J.P., Jr., Harrison, M.B., and Parker, W.D., Jr. (1999). Characterization of cybrid cell lines containing mtDNA from Huntington's disease patients. Biochem. Biophys. Res. Commun. 261, 701-704. (Pubitemid 29408121)
161. Tabrizi, S.J., Cleeter, M.W., Xuereb, J., Taanman, J.W., Cooper, J.M., and Schapira, A.H. (1999). Biochemical abnormalities and exci-totoxicity in Huntington's disease brain. Ann. Neurol. 45, 25-32. (Pubitemid 29036428)
162. Tabrizi, S.J., Workman, J., Hart, P.E., Mangiarini, L., Mahal, A., Bates, G., Cooper, J.M., and Schapira, A.H. (2000). Mitochondrial dysfunction and free radical damage in the Huntington R6/2 trans-genic mouse. Ann. Neurol. 47, 80-86. (Pubitemid 30033653)
163. Tabrizi, S.J., Blamire, A.M., Manners, D.N., Rajagopalan, B., Styles, P., Schapira, A.H., and Warner, T.T. (2005). High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology 64, 1655-1656. (Pubitemid 40617715)
164. Tang, B., Seredenina, T., Coppola, G., Kuhn, A., Geschwind, D.H., Luthi-Carter, R., and Thomas, E.A. (2011). Gene expression pro-filing of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease. Neurobiol. Dis. 42, 459-467.
165. The Huntington's Disease Collaborative Research Group (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
166. Trimmer, P.A. and Bennett, J.P., Jr. (2009). The cybrid model of sporadic Parkinson's disease. Exp. Neurol. 218, 320-325.
167. Trounce, I. and Wallace, D.C. (1996). Production of transmitochon-drial mouse cell lines by cybrid rescue of rhodamine-6G pre-treated L-cells. Somat. Cell Mol. Genet. 22, 81-85. (Pubitemid 26177599)
168. Tsang, T.M., Haselden, J.N., and Holmes, E. (2009). Metabonomic characterization of the 3-nitropropionic acid rat model of Huntington's disease. Neurochem. Res. 34, 1261-1271.
169. Tsukihara, T., Aoyama, H., Yamashita, E., Tomizaki, T., Yamaguchi, H., Shinzawa-Itoh, K., Nakashima, R., Yaono, R., and Yoshikawa, S. (1996). The whole structure of the 13-subunit oxidized cyto-chrome c oxidase at 2.8 A. Science 272, 1136-1144.
170. Turner, C., Cooper, J.M., and Schapira, A.H. (2007). Clinical correlates of mitochondrial function in Huntington's disease muscle. Mov. Disord. 22, 1715-1721. (Pubitemid 47597594)
171. Turunen, M., Olsson, J., and Dallner, G. (2004). Metabolism and function of coenzyme Q. Biochim. Biophys. Acta 1660, 171-199. (Pubitemid 38125244)
172. Valenza, M., Rigamonti, D., Goffredo, D., Zuccato, C., Fenu, S., Jamot, L., Strand, A., Tarditi, A., Woodman, B., Racchi, M., et al. (2005). Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J. Neurosci. 25, 9932-9939. (Pubitemid 41528031)
173. Valenza, M., Leoni, V., Karasinska, J.M., Petricca, L., Fan, J., Carroll, J., Pouladi, M.A., Fossale, E., Nguyen, H.P., Riess, O., et al. (2010). Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes. J. Neurosci. 30, 10844-10850.
174. van Dellen, A. and Hannan, A.J. (2004). Genetic and environmental factors in the pathogenesis of Huntington's disease. Neurogenetics 5, 9-17. (Pubitemid 38297468)
175. van den Heuvel, L. and Smeitink, J. (2001). The oxidative phospho-rylation (OXPHOS) system: nuclear genes and human genetic diseases. Bioessays 23, 518-525. (Pubitemid 32575612)
176. van der Giezen, M. and Tovar, J. (2005). Degenerate mitochondria. EMBO Rep. 6, 525-530. (Pubitemid 40973960)
177. Velier, J., Kim, M., Schwarz, C., Kim, T.W., Sapp, E., Chase, K., Aronin, N., and DiFiglia, M. (1998). Wild-type and mutant hun-tingtins function in vesicle trafficking in the secretory and endo-cytic pathways. Exp. Neurol. 152, 34-40. (Pubitemid 28366964)
178. Verbessem, P., Lemiere, J., Eijnde, B.O., Swinnen, S., Vanhees, L., Van Leemputte, M., Hespel, P., and Dom, R. (2003). Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 61, 925-930. (Pubitemid 37248646)
179. Vogelstein, B., Lane, D., and Levine, A.J. (2000). Surfing the p53 network. Nature 408, 307-310.
180. Vonsattel, J.P. and DiFiglia, M. (1998). Huntington disease. J. Neuropathol. Exp. Neurol. 57, 369-384. (Pubitemid 28237321)
181. Vonsattel, J.P., Myers, R.H., Stevens, T.J., Ferrante, R.J., Bird, E.D., and Richardson, E.P. (1985). Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44, 559-577. (Pubitemid 16196286)
182. Wang, Z.C., Wang, X.M., Jiao, B.H., Jin, Y.X., Miao, M.Y., Zhu, K.J., and Ni, Q.G. (2003). Detection of mitochondrial DNA deletion by a modified PCR method in a 60Co radiation-exposed patient. IUBMB Life 55, 133-137.
183. Weydt, P., Pineda, V.V., Torrence, A.E., Libby, R.T., Satterfield, T.F., Lazarowski, E.R., Gilbert, M.L., Morton, G.J., Bammler, T.K., and Strand, A.D. (2006). Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab. 4, 349-362. (Pubitemid 44645069)
184. Yang, W., Dunlap, J.R., Andrews, R.B., and Wetzel, R. (2002). Aggregated poly-glutamine peptides delivered to nuclei are toxic to mammalian cells. Hum. Mol. Genet. 11, 2905-2917.
185. Yang, L., Calingasan, N.Y., Wille, E.J., Cormier, K., Smith, K., Ferrante, R.J., and Beal, M.F. (2009). Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J. Neurochem. 109, 1427-1439.
186. Young, A.J., Johnson, S., Steffens, D.C., and Doraiswamy, P.M. (2007). Coenzyme Q10: a review of its promise as a neuropro-tectant. CNS Spectr. 12, 62-68. (Pubitemid 46155305)
187. Zabel, C., Mao, L., Woodman, B., Rohe, M., Wacker, M.A., Klare, Y., Koppelstatter, A., Nebrich, G., Klein, O., Grams, S., et al. (2009). A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for Huntington disease. Mol. Cell. Proteomics 8, 720-734.
188. Zhai, W., Jeong, H., Cui, L., Krainc, D., and Tjian, R. (2005). In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell 123, 1241-1253. (Pubitemid 41821782)
189. Zhang, X.D., Wang, Y., Wang, Y., Zhang, X., Han, R., Wu, J.C., Liang, Z.Q., Gu, Z.L., Han, F., Fukunaga, K., et al. (2009). p53 mediates mitochondria dysfunction-triggered autophagy activation and cell death in rat striatum. Autophagy 5, 339-350.
190. Zong, H., Ren, J.M., Young, L.H., Pypaert, M., Mu, J., Birnbaum, M.J., and Shulman, G.I. (2002). AMP kinase is required for mitochon-drial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc. Natl. Acad. Sci. USA 99, 15983-15987. (Pubitemid 35462735)